# Boston University CCCR

> **NIH NIH P30** · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $842,673

## Abstract

OVERALL
ABSTRACT
The Boston University P30 CCCR emphasizes rheumatic and musculoskeletal disease (RMD) epidemiology and
patient-oriented clinical research. The first cycle of our CCCR has been highly productive and successful in
expanding the network of RMD researchers leveraging our expertise and resources. Our CCCR will continue to
serve as a central resource for clinical researchers in RMDs locally, nationally, and internationally who represent
our broader research community. Our CCCR's broad aim is to conduct and disseminate high quality clinical
research in RMDs using state-of-the-art methods and to serve as a central resource for such methods for our
dynamic research community. The Center has also trained many leading clinical researchers in RMDs, and most
continue to have active interactions and collaborations with the Center, including accessing advanced
methodology support and unique data resources. In this cycle, we will continue to provide advanced methodology
support, including in new areas, make our protocols and data resources available, providing training in protocols,
and function as a resource for clinical expertise to those who require such clinical insights and guidance. We will
continue a Pilot & Feasibility grant program to aid early-stage investigators and/or attract new investigators into
the RMD field. We will expand our educational programming and outreach efforts to broaden our impact and
research network. A key focal point of this CCCR is a weekly clinical research meeting known as Research
Accelerator, in which ongoing and proposed research projects are critically evaluated. Specifically, we provide
input into study design, protocol development, and analysis help for multiple projects both within and outside the
Core group, as well as critical feedback for abstracts, manuscripts, presentations, posters, and grants. The
success of our Research Accelerator is evidenced by the publication productivity and grant support garnered by
the Core group and collaborating research community. Our CCCR currently supports 26 grants with Core faculty
as PI, including the current P30, 1 U19, 7 R01s, 1 T32, 1 K23, 1 K24, 11 foundation grants, and 3 industry
research grants, as well as several clinical trials. In addition, CCCR funding has supported ~52 original peer-
reviewed annually in peer-reviewed journals (210 in past 4 years of this cycle), most in leading arthritis journals
and some in leading general medical journals, reflecting both our Core faculty's own research and the Center's
successful assistance and partnerships in the research community. The overall goal of this Center is to carry out
and disseminate high-level clinical research utilizing advanced methodology and informed by biological scientific
discoveries. Ultimately, we aim to prevent the RMDs we are studying and to improve the lives of those living with
these diseases.

## Key facts

- **NIH application ID:** 10928384
- **Project number:** 2P30AR072571-06
- **Recipient organization:** BOSTON UNIVERSITY MEDICAL CAMPUS
- **Principal Investigator:** TUHINA NEOGI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $842,673
- **Award type:** 2
- **Project period:** 2019-09-11 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10928384

## Citation

> US National Institutes of Health, RePORTER application 10928384, Boston University CCCR (2P30AR072571-06). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10928384. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*